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Summary
The induction of cachectin/tumor necrosis factor (TNF) synthesis by bacterial endotoxins is
a process that entails activation at several levels. Cachectin/TNF gene transcription is accelerated,
leading to rapid accumulation ofmP NA within the macrophage cytosol. In addition, translational
derepression occurs, leading to far more efficient message utilization. Through the use of post-
transcriptional reporter constructs, we now demonstrate that certain agents capable of inhibiting
cachectin/TNF biosynthesis operate through different mechanisms. In RAW 264.7 macrophages,
pentoxifylline blocks cachectin/TNF mRNA accumulation but has no effect upon the efficiency
of reporter mRNA translation. Dexamethasone, on the other hand, has only a modest effect
on cachectin/TNF mkNA accumulation, but strongly impedes translational derepression.
Combined application of dexamethasone and pentoxifylline to macrophages causes a greater
suppression of cachectin/TNF biosynthesis than can be achieved by either agent alone. These
findings suggest that the signaling pathway activated by endotoxin is branched, and that selective
inhibition of different parts of the pathway may be achieved through the use of distinct agents.
I
t is widely accepted that bacterial endotoxins (LPS) pro-
voke shock and tissue injury by eliciting the release oftoxic
factors from reticuloendothelial cells of the host (1). It also
appears that cachectin/TNF is one of the principal endoge-
nous factors involved in this process (2-4).
It is known that glucocorticoid agonists blockthe biosyn-
thesis of cachectin/TNF (5). These agents cause a partial in-
hibition of cachectin/TNF mRNA accumulation; however,
more important to their overall effect, they have been shown
to markedly depress the translation of the mRNA that is
produced (5) . Among other agents that act to inhibit the
release of cachectin/TNF, inhibitors of phosphodiesterase
(most notably pentoxifylline), and cyclic AMP analogues seem
to block the accumulation of cachectin/TNF mRNA (6).
No studies of their effects at the translational levelhave been
reported.
In this paper, we present evidence that the signaling pathway
leading to affect the synthesis ofcachectin/TNF is bifurcated,
and that glucocorticoids and pentoxifylline affect different
branches of this pathway.
Cell Culture.
￿
Cellsof the mouse macrophageline RAW 264.7,
as well as primary mouse macrophages, were studied in these ex-
periments. 1,929 cells were used for cachectin/TNF assay.
RAW 264.7 cells were transfected with two constructsdesigned
to assess posttranscriptional activation ofcachectin/TNF synthesis.
In each construct, CAT transcription is driven by the SV40 late
promoter. In construct A, the CAT coding sequence is followed
by most of the human cachectin/TNF 3'-untranslated region. In
construct B (the control), no cachectin/TNF sequence is present.
The RAW 264.7 cell lines transfected with constructs A and B
have been described elsewhere (7); construct "A" is equivalent to
construct "II" of that publication, and construct "B" is equivalent
to construct "IX."
RAW 264.7 cells were maintained as previouslydescribed (7).
Cells were plated at a density of -10s per well (1.6 cm diameter)
for use in experiments involving LPS, pentoxifylline, and dexa-
methasone.
Mouse peritoneal macrophages were obtained as previously de-
scribed (8). LPS (from Escherichia coli, strain 0127:B8; Di~o Labora-
tories, Detroit, MI) was added to a final concentration of 1 /4g/ml
in all experiments in which it was used. Varying concentrations
of dexamethasone and pentoxifylline were used, as indicated.
Dexamethasone (Fluka, Ronkonkoma, NY) and pentoxifylline
(Hoechst-Roussell, Somerville, NJ) were added 1 h before addi-
tion ofLPS in all instances. Quantitation ofcachectin/TNF mRNA,
CAT mRNA, and actin mRNA (control) was performed 4 h after
activation by LPS. Cells and medium from identical cultures were
harvested for measurement of CAT activity and cachectin/TNF
activity 6 h after activation by LPS. D929 (mouse fibrosarcoma)
were grown and passaged in DME supplemented with 10% FCS.
CAT Assay.
￿
CAT assaywas performed according to the thin-
layer chromatography method of Gorman et al. (9). Quantitation
ofenzyme activity was achieved by scraping the 3-acetylated form
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tillation fluid.
mRNA Analysis.
￿
Cytoplasmic mRNA was isolated fromRAW
264.7 cells, or from peritoneal macrophages (7), and used for
Northern blot analysis . RNA was resolved in formaldehyde gels,
and transferred to nylonmembranes by electroblotting . Probes for
cachectin/TNF and actin mRNAs were produced by randomly
primed DNA synthesis . An antisenseRNA probe wasused to de-
tect CATmRNA .
Cachectin/TNF Assay .
￿
Cachectin/TNF assay was carried out
using cycloheximide-treated IJ929 cells, as previously described (10) .
Results were expressed in terms of nanograms TNF per milliliter
of culture medium, or in terms of percent inhibition of the re-
sponse to LPS .
Results
Thepresence of thecachectin/TNF 3'-untranslated region
permits translational derepression ofCAT synthesis to occur
Figure 1.
￿
The effect of pentoxifylline
(A) and of dexamethasone (B) on the in-
duction ofCAT activity and TNF release
by RAW 264.7 cells transfected with con-
struct A. Cells that were not treated with
pentoxifylline or dexamethasone served as
controls ; percent inhibition of the response
to endotoxin by pentoxifylline or dexa-
methasone was calculated with reference to
the amount of CAT or TNF that could be
produced by LPS-activated control cells .
Values for TNF represent the mean of qua-
druplicate assays ; single CAT assays were
performed .
in cells containing constructA(Fig. 1,A andB) . Whiledexa-
methasone and pentoxifylline each caused strong inhibition
of cachectin/TNF release from these cells, only dexametha-
sone caused adetectable inhibition ofCAT expression . Inhi-
bition ofCAT biosynthesis required the application of slightly
higher concentrations of dexamethasone than were required
to inhibit cachectin/TNF synthesis . Moreover, the maximum
inhibition ofCAT synthesis fell slightly short of the inhibi-
tion of cachectin/TNF synthesis.
The effects of dexamethasoneand pentoxifylline upon ex-
pression ofCAT inRAW 264.7 cells transfected with con-
structAwere then compared with the effectsupon cells trans-
fected with construct B (Fig . 2, A and B) . As previously
described, an endotoxin strongly induces CAT expression in
cells bearing construct A, but has a negligible effect upon
CATexpression in cells bearing constructB . Both dexameth-
asoneand pentoxifylline inhibitedthe releaseofcachectin/TNF
from LPS-inducedRAW 264.7 cells, and as previously, only
Figure 2 .
￿
The effects of dexamethasone and pentoxifylline on the induction ofCAT activity and TNF release by RAW 264.7 cells transfected
with construct A (A), or construct B (B) . TNF release is presented in terms of nanograms/milliliter culture medium . Assays were performed in
quadruplicate . Cultures were left unstimulated (-) or were stimulated (+) by LPS . Either no addition (0), or the addition of dexamethasone
(DEX ; 10 AM) or pentoxifylline (PTX ; 100 Ag/ml) was made to the culture 1 h before the time of LPS stimulation . Autoradiograms of CAT
assays performed on cultures are displayed below the corresponding TNF assays ; the CAT induction ratio measured for each sample is displayed
below each autoradiogram . (C) TNFmRNA and actin mRNA (control) were examined in cultures displayed in (A) and (B) by Northern
blotting. (Lanes 1-6) cells containing constructA. (Lanes 7-12) Cells containing construct B. Order of samples is the same as that shown
in A and B .
392
￿
Dexamethasone and Nntoxifylline Inhibition of CachectinFigure 3.
￿
The effect of dexamethasone (10 14M) and pentoxifylline
(100 Wg/ml), alone or in combination, on the induction ofCAT and
TNF activities, and on the accumulation of CATmRNA and TNF
mRNA in RAW 264.7 cells transfected with construct A. Data are
presented according to the same format as that described in Fig. 2 .
CAT mRNA, as well as TNF mRNA, was examined by Northern
blotting. The effect of combined treatment with dexamethasone and
pentoxifylline (DEX+PTX) is also assessed . lanes 1-8 of the
Northern blot correspond, sequentially, to the order of the TNF and
CAT assays .
dexamethasone suppressed CAT biosynthesis in cells trans-
fected with construct A. No such suppressive effect was noted
in cells transfected with construct B. Thus, the inhibitory
effect ofdexamethasone, like the translational activating effect
of LPS, is dependent upon sequences present in the 3'-un-
translated region of cachectin/TNF.
It was further observed that dexamethasone had a rather
modest inhibitory effect on cachectin/TNFmRNA accumu-
lation in both cell lines (Fig. 2 C) . Pentoxifylline had a far
stronger effect : cachectin/TNFmRNA levels were depressed
by90% or more in each line . Thus, dexamethasone and pen-
toxifylline caused inhibition ofcachectin/TNF synthesis by
different mechanisms .
Combined application of dexamethasone and pentoxifyl-
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C3H/HeN Macrophage
Addition 0 DEX PTX DEX+PTX
Figure 4 .
￿
The effect of dexamethasone (10 uM) and pentoxifylline
(100 1~g/ml), alone or in combination, on the induction of TNF and
on the accumulation of TNF mRNA in primary macrophages de-
rived from C3H/HeN mice. Lanes 1-8 of the Northern blot cor-
respond, sequentially, to the order of the TNF assays.
line caused more pronounced inhibition of cachectin/TNF
synthesis than either agent alone (Fig. 3) . Neither agent sub-
stantially affected the levels ofCAT mRNA expressed within
the same cells. CAT mRNA, unlike cachectin/TNFmRNA,
was not subject to induction by LPS in this experiment, al-
though on some occasions (not shown) a comparatively weak
inducing effect was noted .
As demonstrated in Fig. 4, macrophages derived from
C3H/HeN mice are also affected by both dexamethasone and
pentoxifylline, which act to suppress the production of
cachectin/TNF. As inRAW 264.7 cells, dexamethasone has
little or no effect upon cachectin/TNF mRNA accumula-
tion, whereas pentoxifylline markedly diminishes the accumu-
lation ofthis mRNA . When applied to primary macrophages
in combination, dexamethasone and pentoxifylline achieve
a higher degree of suppression than either agent is capable
of causing by itself.
Discussion
Recently, we demonstrated that cachectin/TNF synthesis
largely depends upon translational derepression (7) . In resting
RAW 264.7 cells, cachectin/TNF translation is extremely
inefficient ; however, following activation by LPS, the rate
of translation per unitmRNA increases some 200-fold . Thus,
one part of LPS signaling elicits translational activation.In the present study we have demonstrated that pentox-
ifylline and dexamethasone, which both inhibit the induc-
tion o£ cachectin/TNF synthesis by LPS, achieve their in-
hibitory effects through different mechanisms. Dexamethasone
exerts a strong inhibitory effect upon translational derepres-
sion, and weakly inhibits the accumulation ofcachectin/TNF
mRNA. Pentoxifylline, by contrast, strongly inhibits the ac-
cumulation of cachectin/TNF mRNA, but has no effect upon
the translational derepression process. At present, little is
known about the molecular events that follow stimulation
of the macrophage by LPS. We may now conclude, however,
that the signaling pathway bifurcates at least once, so as to
allow activation of TNF synthesis at pretranslational and trans-
lational levels. These features of the activation pathway are
independently inhibitable.
Since dexamethasone blocks both cachectin/TNF mRNA
accumulation and, to a greater extent, the effective transla-
tion ofthis mRNA, we consider it like:y that this agent acts
at a very proximal point in the chain of events that follow
contact between LPS and the cell. Conceivably, dexametha-
sone might influence the behavior of the LPS receptor itself,
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or the actions of the early transducing protein involved in
the response. The comparatively selective effect of pentox-
ifylline may reflect inhibition at a level well removed from
the LPS receptor. As one possible interpretation, it might
be suggested that pentoxifylline diminishes LPS-induced tran-
scription of the cachectin/TNF gene. However, we are reluc-
tant to draw this conclusion since no measurements of tran-
scription have yet been performed.
Since dexamethasone and pentoxifylline prevent cachectin/
TNF synthesis by exercising inhibition at separable points
in the LPS signaling pathway, it is not surprising to note
that the two agents togetherblock cachectin/TNF synthesis
more effectively than either alone. This effect is demonstrable
in primary macrophage cultures, just as in RAW 264.7 cells,
and presumably has a similar molecular basis. It is probable
that the biosynthesis of other cytokines is similarly affected
by pentoxifylline, alone or in combination with dexametha-
sone, although we have yet to investigate this issue. It is also
possible that the combined use of pentoxifylline and dexa-
methasone in vivo would attenuate the lethal effect of endo-
toxin more effectively than either agent administered by itself.
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